In what Science magazine has dubbed “Novo Nordisk’s Canadian Mistake,” Ozempic is soon to come off patent in Canada, opening ...

GLP-1 medications offer promising benefits for obesity and diabetes patients, with studies showing reduced heart attack risk and potential applications for addiction treatment.

“According to the latest figures released by the NHS, dementia diagnosis is at a record high in England. “This is great news for residents, as increased awareness results in increased ...

Results from this study show that there is a direct correlation between the use of anti-obesity medications and testosterone levels,” the study author said.

Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.

Odds are you’ve heard of GLP-1 drugs like Ozempic for managing type 2 diabetes and shedding pounds. But have you ever wondered what Ozempic does to your brain? Recent research suggests it might ...

New study suggests that Novo Nordisk’s Ozempic may lower dementia risk and nicotine use. Meanwhile, UnitedHealth Group’s cyberattack woes aren’t over yet.

Obesity and diabetes drugs, particularly semaglutides like Wegovy and Ozempic, may reduce a person’s risk of dementia, a new study suggests. Researchers found these medications show promise in ...

A study finds a drug known for weight loss may also help to reduce dementia. The study looked at semaglutide, the scientific name for Novo Nordisk's (NVO) (DK:NOVO.B) Ozempic, with the intent of ...

A new study adds to mounting evidence showing that drugs like Ozempic don’t just treat diabetes — they can also prevent it. The new paper, published Wednesday in The New England Journal of ...

Ozempic and Wegovy have the same active ingredient, semaglutide, in different doses, and mimic the hormone glucagon-like peptide-1.